Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia
Status:
Not yet recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
In-vitro studies revealed that nafamostat mesylate has antiviral activity against Severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and anti-inflammatory and
anti-coagulation effect. However, there is no clinical studies on the efficacy of nafamostat
in patients with COVID-19.
This study is conducted to evaluate the clinical efficacy of nafamostate mesylate in adult
patients hospitalized with COVID-19 pneumonia.